Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population

October 1, 2009 updated by: Boehringer Ingelheim

Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Patient Population

Data collection for better patient characterization in a highly treatment experienced population. Studying the clinical practice for the treatment of HIV multiexperienced patients in the real life.

The research will be divided into two phases:

  • The first phase intends to define and understand the clinical practice using a questionnaire about general topics: definitions of multiexperienced patients and VL failure, therapeutic strategies and behaviour in particular cases.
  • The second part of the research will collect the clinical data of double PIs failure patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

428

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Ancona, Italy
        • Boehringer Ingelheim Investigational Site
      • Bari, Italy
        • Boehringer Ingelheim Investigational Site
      • Benevento, Italy
        • Boehringer Ingelheim Investigational Site
      • Bisceglie, Italy
        • Boehringer Ingelheim Investigational Site
      • Bologna, Italy
        • Boehringer Ingelheim Investigational Site
      • Brescia, Italy
        • Boehringer Ingelheim Investigational Site
      • Busto, Italy
        • Boehringer Ingelheim Investigational Site
      • Caserta, Italy
        • Boehringer Ingelheim Investigational Site
      • Catania, Italy
        • Boehringer Ingelheim Investigational Site
      • Cremona, Italy
        • Boehringer Ingelheim Investigational Site
      • Firenze, Italy
        • Boehringer Ingelheim Investigational Site
      • Genova, Italy
        • Boehringer Ingelheim Investigational Site
      • Legnano, Italy
        • Boehringer Ingelheim Investigational Site
      • Milano, Italy
        • Boehringer Ingelheim Investigational Site
      • Napoli, Italy
        • Boehringer Ingelheim Investigational Site
      • Padova, Italy
        • Boehringer Ingelheim Investigational Site
      • Palermo, Italy
        • Boehringer Ingelheim Investigational Site
      • Pavia, Italy
        • Boehringer Ingelheim Investigational Site
      • Roma, Italy
        • Boehringer Ingelheim Investigational Site
      • Sassari, Italy
        • Boehringer Ingelheim Investigational Site
      • Torino, Italy
        • Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

HIV patients

Description

Inclusion Criteria:

Patients double PIs failure

Exclusion Criteria:

Not Applicable

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To study in the clinical practice the choice of a specific salvage regimen for multiexperienced patients.
Time Frame: 48 weeks
48 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Reason of each VL failure or switching
Time Frame: 48 weeks
48 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2007

Primary Completion (Actual)

October 1, 2008

Study Registration Dates

First Submitted

January 31, 2008

First Submitted That Met QC Criteria

February 12, 2008

First Posted (Estimate)

February 13, 2008

Study Record Updates

Last Update Posted (Estimate)

October 2, 2009

Last Update Submitted That Met QC Criteria

October 1, 2009

Last Verified

October 1, 2009

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1182.130

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infections

Clinical Trials on TPV

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe